

Please try another search
AusCann Group Holdings Limited is an Australia-based company, which is focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Neuvis is its controlled-dose technology platform, which delivers cannabinoids (CBD) to human patients, with the first product in the range being a THC:CBD hard-shell capsule in a 1:1 ratio, in both a 2.5mg and 10mg strength. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol and cannabidiol whole plant extracts in a ratio to target pain and inflammation in dogs. DermaCann is its CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. MicroMAX is an encapsulation technology, which helps to enhance the delivery of cannabis-based animal health products. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.
Name | Age | Since | Title |
---|---|---|---|
Marc Russo | - | 2020 | Chief Medical Advisor & Chairman of Medical Advisory Board |
Robert Clifford | - | 2021 | Independent Non-Executive Director |
Tod Stephen McGrouther | 60 | 2021 | Independent Non-Executive Chairman of the Board |
Christopher Mews | - | 2019 | CFO & Director |
Peter Gonski | - | 2020 | Member of Medical Advisory Board |
Sachin Shetty | - | 2020 | Member of Medical Advisory Board |
Peter Georgius | - | 2020 | Member of Medical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review